ERBB2 and metastatic malignant neoplasm: Considering their modest efficacy and the current situation with more available antibody-drug conjugates and tyrosine kinase inhibitors [22,24], HSP90 inhibitors are not an attractive option for HER2 (+) metastatic cancers.